Concepedia

ChaoYu Jin

CJ

Statistics

Publications

5

Citations

146

H-Index

5

Active since

2017

Affiliations

AstraZeneca (United States)(Current)

AstraZeneca (Poland)

Bioscience Research

AstraZeneca (Finland)

AstraZeneca (Germany)

ChaoYu Jin is an author at AstraZeneca (United States) specializing in medicine, pharmacology, and high-density lipoprotein metabolism.

Publications per year

2017–2021

5

Publications

5

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma

Yanan Zheng, Rajesh Narwal, ChaoYu Jin et al. · Clinical Pharmacology & Therapeutics · 2017 · 57 citations · Full text

, , +17

MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High‐Density Lipoprotein, and Low‐Density Lipoprotein Receptor–Mediated Reverse Cholesterol Transport

Richard T. De George, Liron Abuhatzira, Susan M. Stoughton et al. · Journal of the American Heart Association · 2021 · 27 citations · Full text

, , +17

Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial

John E. Le Lay, Qun Du, Minal B. Mehta et al. · Science Translational Medicine · 2021 · 24 citations

, , +17

Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design

Marc P. Bonaca, Richard T. De George, David A. Morrow et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 2021 · 22 citations · Full text

, , +17

Exposure-efficacy and safety analysis of durvalumab in patients with urothelial carcinoma (UC) and other solid tumors.

ChaoYu Jin, Yanan Zheng, Xiaoping Jin et al. · Journal of Clinical Oncology · 2017 · 16 citations

, , +17

1–5 of 5